For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin, Hisamitsu Launch Cancer Pain Treatment Abstral Sublingual Tablets
December 13, 2013
- IPSN Proposes Life Sciences Business Platform in Tokyo to Be Included in Mr Abe’s Special Zones
December 12, 2013
- Mochida Buys Back 100,000 Shares
December 12, 2013
- New Osaka Logistics Center to Go Live in January: Taisho
December 12, 2013
- Otsuka, Lundbeck to Codevelop Vaccine for Alzheimer’s Disease
December 12, 2013
- US FDA Advisory Panel Backs Takeda Ulcerative Colitis Drug
December 11, 2013
- Santen Sets Up Local Subsidiary in Singapore
December 11, 2013
- Takeda to Establish New CIO Post, Appoint Former Nestlé Exec
December 11, 2013
- Ono to Launch PI Study on Peptide-Cocktail Vaccine for HCC
December 11, 2013
- GSK Launches Asthma Treatment Relvar
December 11, 2013
- Drug Makers Invest in Developing AD Treatments
December 10, 2013
- Ethical Drug Sales Up 2.5% in October: Crecon Report
December 10, 2013
- Santen Files MAA for Ciclosporin for Dry Eye Disease in Europe
December 10, 2013
- Veep Kawasaki to Be Elevated to President of inVentiv Health Japan
December 9, 2013
- Survey Finds 1.7-Fold Increase in Patients Prescribed DPP-4 Inhibitors Over 2-Year Period: MDV
December 9, 2013
- ViiV Healthcare Files NDA for Anti-HIV Treatment Dolutegravir in Japan
December 9, 2013
- “Objective Accomplished,” Daiichi Sankyo to Terminate Ranmark Copromotion with AZ at Year-End
December 9, 2013
- Fujifilm to Initiate Joint PII Study of AD Treatment with ADCS
December 9, 2013
- Generics Showed Strong Growth in 1st Half of FY2013 Despite Lack of New Measures to Promote Their Use
December 6, 2013
- Kyowa Kirin Shutters Yokkaichi Plant
December 6, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…